Government health advisers say a once-a-day respiratory inhaler from GlaxoSmithKline appears...
GlaxoSmithKline has announced the completion of the disposal of half of its 12.4% shareholding...
The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and...
Britain's GlaxoSmithKline PLC and Switzerland's Novartis AG have completed a three-part deal that will offer the British company's shareholders a 4 billion pound ($6.17 billion) windfall.
Pharmaceutical companies sponsoring clinical trials showed strong improvement in their relationships with global investigative sites, according a recent survey.
GSK voluntary recalled Alli last March after finding some packages in stores didn't contain real alli, indicating tampering after shipment. The Food and Drug Administration is still investigating.
Edmond de Rothschild Investment Partners announced today that its BioDiscovery 3 portfolio company, GlycoVaxyn AG, a privately held specialist vaccine biopharmaceutical company, has been acquired by GlaxoSmithKline in an all-cash transaction valuing the company at approximately $212M.
Following a less than flattering financial performance in 2014, GlaxoSmithKline is realigning its operating structure with its corporate objectives and cashing in on its assets in the process, as the company seeks to drive up external investments and deliver stronger shareholder returns in the long term, says an analyst with research and consulting firm GlobalData.
GlaxoSmithKline has announced the simultaneous availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the US. Over the past 15 months, GSK has launched four inhaled respiratory therapies in the US, all delivered in its Ellipta inhaler.
Array BioPharma today announced that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.
After an expert meeting this week, WHO said there is now enough information to conclude that the two most advanced Ebola vaccines — one made by GlaxoSmithKline and the other licensed by Merck and NewLink — have "an acceptable safety profile."
Roivant Neurosciences has entered into an agreement with GlaxoSmithKline for the acquisition of SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders.
Agenus and its partner GlaxoSmithKline have reported that the ZOE-50 Phase III study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2% in adults aged 50 years and older compared to placebo.
GlaxoSmithKline released details of a restructuring program Wednesday, which included 900 layoffs.
Clovis Oncology has entered into a clinical trial collaboration with GlaxoSmithKline to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC).
The European Medicines Agency (EMA) has given scientific advice to GSK on its development plan for an Ebola vaccine. This is the first time in the current Ebola outbreak that EMA has given ‘rapid scientific advice’ using an accelerated procedure.
The Swiss agency that regulates new drugs has approved an application for a clinical trial with an experimental Ebola vaccine at the Lausanne University Hospital. Swissmedic said the trial will be conducted among 120 volunteer participants with support from the U.N. World Health Organization.
GlaxoSmithKline Third Quarter 2014 Results Interview with CEO Sir Andrew Witty & CFO Simon Dingemans.October 27, 2014 9:07 am | Videos | Comments
Interview with Sir Andrew Witty, CEO, and Simon Dingemans, CFO announcing the company's Q3 2014 results including a restructuring of the business and a possible partial IPO of ViiV Healthcare.
Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history. It's unclear who will pay for their products, but companies are betting that governments and aid groups will foot the bill.
The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. Still, the agency warned it's not clear whether any of these will work against the deadly virus that has...
ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this $18M milestone payment, Isis has generated $45M of the $70M in upfront and milestone payments Isis is eligible to earn for advancing ISIS-TTRRx in development.
Novartis confirmed today that following completion of the transactions with GlaxoSmithKline and Eli Lilly and Company in the coming months, that the three business leaders of the Novartis divisions at the center of the transaction will leave the Executive Committee of Novartis.
Pharmaceutical companies are refining their sales strategy. GlaxoSmithKline's Dierdre Connelly discusses why with WSJ's Tanya Rivero.
The National Institute of Allergy and Infectious Diseases says an experimental Ebola vaccine is being processed at a facility in Frederick. The vaccine is a joint project between the federal agency and GlaxoSmithKline.
The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumor types.
The scandal and its repercussions will be felt deep into Big Pharma’s operations in emerging markets, causing a fundamental shift in product marketing approaches involving physicians.
Silarus Therapeutics and Thyritope Biosciences each will receive up to $10M in Series A financing and R&D support from Avalon Ventures and GSK. Both companies will be located at COI Pharmaceuticals in San Diego, the community of innovation established by Avalon Ventures to provide operational support, a fully equipped R&D facility and an experienced leadership team to its life science portfolio companies.
A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been sentenced to prison in a bribery case but may never have to serve that time. China's official Xinhua News Agency said Briton Mark Reilly and his Chinese co-defendants were given a three-year reprieve at their sentencing Friday.
- Page 1